MCID: LNG111
MIFTS: 56

Lung Non-Squamous Non-Small Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards integrated aliases for Lung Non-Squamous Non-Small Cell Carcinoma:

Name: Lung Non-Squamous Non-Small Cell Carcinoma 12 15
Non- Squamous Nsclc 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080521
NCIt 50 C135017

Summaries for Lung Non-Squamous Non-Small Cell Carcinoma

Disease Ontology : 12 A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.

MalaCards based summary : Lung Non-Squamous Non-Small Cell Carcinoma, also known as non- squamous nsclc, is related to exanthem and lung cancer susceptibility 3. An important gene associated with Lung Non-Squamous Non-Small Cell Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Osimertinib and afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and thyroid, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Non-Squamous Non-Small Cell Carcinoma

Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 exanthem 29.0 VEGFA PDCD1 KRAS HRAS ERBB2 EGFR
2 lung cancer susceptibility 3 28.9 VEGFA STK11 ROS1 KRAS KDR HRAS
3 hepatic flexure cancer 10.4 KRAS HRAS
4 trachea carcinoma in situ 10.4 KRAS HRAS
5 signet ring basal cell carcinoma 10.4 KRAS HRAS
6 cobblestone retinal degeneration 10.4 KRAS HRAS
7 signet ring lung adenocarcinoma 10.4 EML4 EGFR ALK
8 immature teratoma of ovary 10.3 KRAS HRAS
9 pancreatic signet ring cell adenocarcinoma 10.3 KRAS HRAS
10 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 PDCD1LG2 CD274
11 descending colon cancer 10.3 KRAS HRAS
12 pleomorphic carcinoma 10.3 EGFR CD274 ALK
13 ampulla of vater benign neoplasm 10.3 KRAS HRAS
14 transverse colon cancer 10.3 KRAS HRAS
15 periampullary adenoma 10.3 KRAS HRAS
16 pediatric fibrosarcoma 10.3 ROS1 EML4 ALK
17 malignant giant cell tumor of the tendon sheath 10.3 ROS1 ALK
18 peritoneal mesothelioma 10.3 EGFR CD274 ALK
19 lung sarcomatoid carcinoma 10.3 EML4 ALK
20 bone giant cell sarcoma 10.3 KRAS HRAS
21 mesenchymal cell neoplasm 10.3 ROS1 EML4 ALK
22 appendiceal neoplasm 10.3 KRAS HRAS
23 gallbladder benign neoplasm 10.3 KRAS HRAS
24 hemifacial spasm 10.3 VEGFA TYMS
25 primary mediastinal large b-cell lymphoma 10.3 PDCD1LG2 CD274
26 acneiform dermatitis 10.3 KRAS HRAS EGFR
27 thymic carcinoma 10.3 PDCD1 EGFR CD274
28 appendix adenocarcinoma 10.3 KRAS HRAS
29 mucinous lung adenocarcinoma 10.3 ROS1 KRAS HRAS
30 skin papilloma 10.3 KRAS HRAS EGFR
31 wolffian duct adenocarcinoma 10.3 KRAS HRAS
32 respiratory system benign neoplasm 10.3 KRAS HRAS EGFR
33 testicular lymphoma 10.3 PDCD1LG2 PDCD1 CD274
34 lung adenoma 10.3 KRAS HRAS EGFR
35 adenosquamous carcinoma 10.3 KRAS EGFR CD274
36 bronchiolo-alveolar adenocarcinoma 10.2 KRAS HRAS EGFR
37 colonic benign neoplasm 10.2 KRAS HRAS EGFR
38 central nervous system hemangioma 10.2 VEGFA RET
39 myopathy, distal, 1 10.2 PDCD1LG2 PDCD1 CD274
40 lymphoepithelioma-like carcinoma 10.2 PDCD1 EGFR CD274 ALK
41 arteriovenous malformation 10.2 VEGFA KRAS HRAS
42 inflammatory myofibroblastic tumor 10.2 ROS1 EML4 ALK
43 noonan syndrome-like disorder with loose anagen hair 1 10.2 KRAS HRAS
44 thymus gland disease 10.2 EGFR CTLA4 CD274
45 thymus cancer 10.2 EGFR CTLA4 CD274
46 pleural disease 10.2 VEGFA GART EGFR
47 anus cancer 10.2 KRAS HRAS EGFR CD274
48 uterine benign neoplasm 10.2 VEGFA KRAS HRAS
49 reproductive organ benign neoplasm 10.2 VEGFA KRAS HRAS
50 septate uterus 10.2 KDR FLT1

Graphical network of the top 20 diseases related to Lung Non-Squamous Non-Small Cell Carcinoma:



Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma

Symptoms & Phenotypes for Lung Non-Squamous Non-Small Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 44)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.76 EGFR HRAS KRAS
2 Decreased viability GR00055-A-2 10.76 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 10.76 KRAS
4 Decreased viability GR00106-A-0 10.76 KRAS
5 Decreased viability GR00221-A-1 10.76 ALK EGFR KDR RET HRAS KRAS
6 Decreased viability GR00221-A-2 10.76 KDR RET FLT1 HRAS KRAS ROS1
7 Decreased viability GR00221-A-3 10.76 ERBB2 KDR HRAS
8 Decreased viability GR00221-A-4 10.76 ALK EGFR ERBB2 KDR RET
9 Decreased viability GR00249-S 10.76 ALK KDR ROS1
10 Decreased viability GR00301-A 10.76 RET KRAS
11 Decreased viability GR00342-S-1 10.76 ROS1
12 Decreased viability GR00381-A-1 10.76 KRAS
13 Decreased viability GR00402-S-2 10.76 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.87 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.87 FLT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.87 RET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.87 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.87 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-171 9.87 FLT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.87 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.87 CD274
23 Increased shRNA abundance (Z-score > 2) GR00366-A-187 9.87 CD274
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.87 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.87 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.87 RET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.87 RET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.87 CD274
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.87 CD274
31 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.87 FLT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.87 ERBB2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.87 RET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.87 KDR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.87 ERBB2 KDR RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 ERBB2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.87 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 CD274 EGFR ERBB2 FLT1 KDR RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.87 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.87 EGFR
42 Decreased cell migration GR00055-A-1 9.73 ALK FLT1
43 Decreased cell migration GR00055-A-3 9.73 EGFR HRAS
44 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 FLT1 RET ROS1

MGI Mouse Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ALK CD274 CTLA4 DHFR EGFR ERBB2
2 cellular MP:0005384 10.39 CD274 DHFR EGFR ERBB2 FLT1 KDR
3 mortality/aging MP:0010768 10.39 ALK CD274 CTLA4 DHFR EGFR EML4
4 growth/size/body region MP:0005378 10.38 ALK DHFR EGFR ERBB2 FLT1 GART
5 cardiovascular system MP:0005385 10.36 CTLA4 DHFR EGFR ERBB2 FLT1 HRAS
6 endocrine/exocrine gland MP:0005379 10.33 ALK CTLA4 EGFR ERBB2 HRAS KIF5B
7 embryo MP:0005380 10.3 DHFR EGFR ERBB2 FLT1 GART KDR
8 hematopoietic system MP:0005397 10.3 CD274 CTLA4 DHFR EGFR FLT1 KDR
9 immune system MP:0005387 10.27 CD274 CTLA4 DHFR EGFR FLT1 KDR
10 integument MP:0010771 10.22 ALK CD274 CTLA4 DHFR EGFR ERBB2
11 digestive/alimentary MP:0005381 10.17 CTLA4 EGFR ERBB2 HRAS KRAS RET
12 muscle MP:0005369 10.14 DHFR EGFR ERBB2 FLT1 HRAS KDR
13 nervous system MP:0003631 10.1 ALK DHFR EGFR ERBB2 FLT1 HRAS
14 neoplasm MP:0002006 10.07 ALK EGFR ERBB2 HRAS KRAS PDCD1
15 liver/biliary system MP:0005370 10.06 CTLA4 DHFR EGFR KDR KRAS PDCD1
16 no phenotypic analysis MP:0003012 9.96 CD274 EGFR HRAS KDR KRAS PDCD1LG2
17 normal MP:0002873 9.9 ALK CTLA4 EGFR ERBB2 FLT1 HRAS
18 respiratory system MP:0005388 9.7 ALK CTLA4 EGFR ERBB2 HRAS KDR
19 skeleton MP:0005390 9.32 ALK CD274 CTLA4 EGFR ERBB2 HRAS

Drugs & Therapeutics for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs for Lung Non-Squamous Non-Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Osimertinib Approved Phase 4 1421373-65-0 71496458
2
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Bevacizumab Approved, Investigational Phase 3 216974-75-3
7
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
8
Maleic acid Experimental Phase 3 110-16-7 444266
9 Albumin-Bound Paclitaxel Phase 3
10 Angiogenesis Inhibitors Phase 3
11 Endothelial Growth Factors Phase 3
12
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
13
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
14
ramucirumab Approved, Investigational Phase 2 947687-13-0
15
Ceritinib Approved Phase 2 1032900-25-6
16
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
17
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
18
Ipilimumab Approved Phase 2 477202-00-9
19
Olaparib Approved Phase 2 763113-22-0 23725625
20
Pembrolizumab Approved Phase 2 1374853-91-4
21
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
22
nivolumab Approved Phase 2 946414-94-4
23
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
24
Gemcitabine Approved Phase 2 95058-81-4 60750
25
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
26
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
27
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Durvalumab Approved, Investigational Phase 2 1428935-60-7
29
Nintedanib Approved Phase 2 656247-17-5 56843413
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
32
Lexatumumab Investigational Phase 2 845816-02-6
33
Ensartinib Investigational Phase 2 1370651-20-9
34
Imetelstat Investigational Phase 2 868169-64-6
35 Antibodies, Blocking Phase 1, Phase 2
36 Vaccines Phase 1, Phase 2
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
38 Endostatins Phase 2 71581480
39 Endostar protein Phase 2
40
Apatinib Phase 2 811803-05-1
41 Antineoplastic Agents, Immunological Phase 2
42 Antimitotic Agents Phase 2
43 Immunosuppressive Agents Phase 2
44 Tubulin Modulators Phase 2
45 Immunologic Factors Phase 2
46 Immunoglobulins, Intravenous Phase 2
47 Antimetabolites Phase 2
48 Anti-Infective Agents Phase 2
49 Antiviral Agents Phase 2
50 Folic Acid Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Unknown status NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
2 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Unknown status NCT03778853 Phase 4 Anlotinib Hydrochloride
3 An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy Recruiting NCT03755869 Phase 4 Anlotinib
4 AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting Recruiting NCT04413201 Phase 4 Afatinib;Osimertinib
5 A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT00806923 Phase 3 Cisplatin;Gemcitabine;Placebo;bevacizumab [Avastin];bevacizumab [Avastin]
6 Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT02954172 Phase 3 Bevacizumab in Combination With Paclitaxel/Carboplatin;IBI305 in Combination with Paclitaxel/Carboplatin
7 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Recruiting NCT04181060 Phase 3 Osimertinib
8 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
9 Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50% Recruiting NCT04547504 Phase 3 Pembrolizumab;Pembrolizumab and Chemotherapy drugs
10 PD-1 Inhibitors and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Recruiting NCT03774732 Phase 3 Pembrolizumab;Chemotherapy
11 A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Recruiting NCT04325698 Phase 3 PF-06439535 (CN);Bevacizumab-EU;Paclitaxel;Carboplatin
12 A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy Recruiting NCT04447118 Phase 3 Pyrotinib;Docetaxel
13 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02193282 Phase 3 Erlotinib Hydrochloride
14 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 Docetaxel
15 A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin Active, not recruiting NCT02810457 Phase 3 FKB238 (bevacizumab);Avastin (bevacizumab);Paclitaxel;Carboplatin
16 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 Paclitaxel;Carboplatin;Pemetrexed Disodium Heptahydrate
17 Anlotinib Combined With Docetaxel as Second-line Treatment of Patients With Wild-type Advanced Non-squamous NSCLC Unknown status NCT03750916 Phase 2 Anlotinib Hydrochloride plus Docetaxel
18 A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR Unknown status NCT01755923 Phase 2 Gefitinib;Docetaxel
19 Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
20 Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab Completed NCT00536640 Phase 2 Erlotinib;Bevacizumab;Gemcitabine;Cisplatin
21 A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy Completed NCT02047344 Phase 2 Antroquinonol
22 A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC Completed NCT00251524 Phase 2 Bevacizumab, Oxaliplatin, Pemetrexed
23 A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC Completed NCT01496742 Phase 2 Placebo;RO5490258;bevacizumab [Avastin];cisplatin/carboplatin;paclitaxel;pemetrexed
24 A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC Recruiting NCT04310007 Phase 2 Cabozantinib S-malate;Docetaxel;Gemcitabine Hydrochloride;Nab-paclitaxel;Paclitaxel
25 A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol Recruiting NCT03737994 Phase 2 Alectinib;Brigatinib;Carboplatin;Ceritinib;Cisplatin;Crizotinib;Ensartinib;Lorlatinib;Pemetrexed
26 A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) Recruiting NCT04173507 Phase 2 Avelumab;Talazoparib;Talazoparib Tosylate
27 A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT03847519 Phase 1, Phase 2 ADXS-503;Pembrolizumab
28 An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With Non-small-cell Lung Cancer (NSCLC) Recruiting NCT03970746 Phase 1, Phase 2 Keytruda Injectable Product;Alimta Injectable Product
29 A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance Recruiting NCT04245085 Phase 2 Atezolizumab;Bevacizumab;Carboplatin;Paclitaxel;Pemetrexed
30 TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Recruiting NCT03786692 Phase 2 Arm A;Arm B
31 A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC Recruiting NCT04163432 Phase 2 Durvalumab;Pemetrexed;Carboplatin
32 A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC Active, not recruiting NCT03468985 Phase 2 Cabozantinib;Cabozantinib S-malate
33 Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer Active, not recruiting NCT02117167 Phase 2 AZD2014;AZD4547;AZD5363;AZD8931;Selumetinib;Vandetanib;Standard maintenance for squamous NSCLC;Pemetrexed;Durvalumab;savolitinib;Olaparib
34 A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response Active, not recruiting NCT02955758 Phase 2
35 Efficacy and Safety of Rh-endostatin(Endostar)Combined With Platinum-based Doublet Chemotherapy and Pembrolizumab as First Line Therapy in Patients With Advanced or Metastatic Non-small-cell Lung Cancer Not yet recruiting NCT04094909 Phase 2 Rh-endostatin
36 CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Not yet recruiting NCT04062708 Phase 2 Durvalumab
37 A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy Not yet recruiting NCT04670913 Phase 2 Camrelizumab;Apatinib
38 A Phase II, Open-Label, Multicenter, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy Not yet recruiting NCT04405674 Phase 2 Tislelizumab;Carboplatin and Nab-paclitaxel;Pemetrexed
39 A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib Not yet recruiting NCT04358562 Phase 2 Gefitinib;Anlotinib
40 A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy Terminated NCT02452463 Phase 2 Nintedanib
41 A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer Terminated NCT00369070 Phase 2 AMG 706;Paclitaxel;Carboplatin
42 S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy Terminated NCT02134912 Phase 2 crizotinib;pemetrexed disodium
43 Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Terminated NCT03041181 Phase 2 Docetaxel;Nivolumab;Gemcitabine;Pemetrexed
44 Phase I-II Study of Avastin®+ Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC Withdrawn NCT00411593 Phase 1, Phase 2 Bevacizumab;Bortezomib
45 A Phase 1b Dose-escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer Completed NCT03780010 Phase 1 TRC105
46 Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC Completed NCT01664754 Phase 1 exemestane;pemetrexed disodium;carboplatin
47 A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor Active, not recruiting NCT02520778 Phase 1 Navitoclax;Osimertinib
48 A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02535325 Phase 1 Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium
49 A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations Unknown status NCT03634059 Apatinib
50 A Open Multicenter Clinical Study to Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI (Unique Molecular Identifier) Technology of Burning Rock Unknown status NCT03337711

Search NIH Clinical Center for Lung Non-Squamous Non-Small Cell Carcinoma

Genetic Tests for Lung Non-Squamous Non-Small Cell Carcinoma

Anatomical Context for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards organs/tissues related to Lung Non-Squamous Non-Small Cell Carcinoma:

40
Lung, Breast, Thyroid, Colon, Skin, Ovary, Endothelial

Publications for Lung Non-Squamous Non-Small Cell Carcinoma

Articles related to Lung Non-Squamous Non-Small Cell Carcinoma:

(show top 50) (show all 381)
# Title Authors PMID Year
1
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. 61
33462883 2021
2
Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. 61
33159605 2021
3
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. 61
33347829 2021
4
Therapeutic strategies in RET gene rearranged non-small cell lung cancer. 61
33771190 2021
5
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 61
33803256 2021
6
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. 61
33682554 2021
7
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. 61
33710815 2021
8
An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. 61
33735884 2021
9
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001. 61
33718016 2021
10
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison. 61
33549014 2021
11
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. 61
33592829 2021
12
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid. 61
33338923 2021
13
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. 61
33554675 2021
14
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. 61
33640623 2021
15
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. 61
33636453 2021
16
EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. 61
33549984 2021
17
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. 61
32632581 2020
18
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England. 61
33332018 2020
19
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease. 61
33489827 2020
20
Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. 61
33126040 2020
21
Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. 61
33153192 2020
22
The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center. 61
33209891 2020
23
Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). 61
33143164 2020
24
Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. 61
32754323 2020
25
Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis. 61
31822198 2020
26
Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. 61
32739743 2020
27
Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. 61
32938626 2020
28
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. 61
32543258 2020
29
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. 61
32619782 2020
30
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. 61
32428850 2020
31
Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer. 61
32387485 2020
32
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. 61
32111518 2020
33
[Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer]. 61
32702797 2020
34
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. 61
32737070 2020
35
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. 61
32720019 2020
36
Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. 61
31318119 2020
37
Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer. 61
32507497 2020
38
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. 61
32508029 2020
39
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. 61
32676310 2020
40
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study 61
32606052 2020
41
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. 61
31332704 2020
42
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. 61
32193809 2020
43
Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. 61
32642151 2020
44
Immunotherapy - new perspective in lung cancer. 61
32728528 2020
45
Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. 61
30847713 2020
46
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. 61
32353934 2020
47
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. 61
32365867 2020
48
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. 61
31231786 2020
49
Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. 61
32132059 2020
50
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer. 61
31420240 2020

Variations for Lung Non-Squamous Non-Small Cell Carcinoma

Cosmic variations for Lung Non-Squamous Non-Small Cell Carcinoma:

9 (show top 50) (show all 17775)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM98616023 ZZEF1 lung,NS,carcinoma,small cell carcinoma c.4892G>T p.G1631V 17:4059282-4059282 6
2 COSM132740059 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 6
3 COSM86240454 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 6
4 COSM86919234 ZSWIM4 lung,NS,carcinoma,small cell carcinoma c.944G>T p.R315L 19:13809152-13809152 6
5 COSM88262283 ZRSR2 lung,NS,carcinoma,small cell carcinoma c.1180G>A p.E394K 23:15822973-15822973 6
6 COSM143073175 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
7 COSM97720347 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
8 COSM87171618 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
9 COSM137271685 ZP2 lung,NS,carcinoma,small cell carcinoma c.1581C>T p.P527= 16:21201455-21201455 6
10 COSM137165710 ZP2 lung,NS,carcinoma,small cell carcinoma c.1608C>T p.P536= 16:21201455-21201455 6
11 COSM131896932 ZNF84 lung,NS,carcinoma,small cell carcinoma c.239-5340A>G p.? 12:133057739-133057739 6
12 COSM101262318 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
13 COSM91416826 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
14 COSM133556674 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1021A>G p.T341A 12:133057739-133057739 6
15 COSM130336034 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
16 COSM98062407 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 6
17 COSM149927805 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 6
18 COSM92021621 ZNF804B lung,NS,carcinoma,small cell carcinoma c.522C>A p.P174= 7:89333504-89333504 6
19 COSM142170486 ZNF804B lung,NS,carcinoma,small cell carcinoma c.273C>A p.P91= 7:89333504-89333504 6
20 COSM142179504 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3504G>C p.L1168= 7:89336735-89336735 6
21 COSM142171430 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3412G>C p.A1138P 7:89336643-89336643 6
22 COSM92048538 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3753G>C p.L1251= 7:89336735-89336735 6
23 COSM92024942 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3661G>C p.A1221P 7:89336643-89336643 6
24 COSM88575001 ZNF804A lung,NS,carcinoma,small cell carcinoma c.862A>T p.K288* 2:184936258-184936258 6
25 COSM88576053 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3281C>T p.S1094F 2:184938677-184938677 6
26 COSM143615605 ZNF804A lung,NS,carcinoma,small cell carcinoma c.607A>T p.K203* 2:184936258-184936258 6
27 COSM143615950 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3026C>T p.S1009F 2:184938677-184938677 6
28 COSM84362584 ZNF777 lung,NS,carcinoma,small cell carcinoma c.1998C>T p.C666= 7:149432274-149432274 6
29 COSM91557035 ZNF746 lung,NS,carcinoma,small cell carcinoma c.887C>T p.A296V 7:149475432-149475432 6
30 COSM151200494 ZNF746 lung,NS,carcinoma,small cell carcinoma c.932C>T p.A311V 7:149475432-149475432 6
31 COSM114445791 ZNF746 lung,NS,carcinoma,small cell carcinoma c.890C>T p.A297V 7:149475432-149475432 6
32 COSM97007058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
33 COSM87004058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1371G>T p.E457D 23:85270913-85270913 6
34 COSM96524071 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1371G>T p.E457D 23:85270913-85270913 6
35 COSM87004493 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
36 COSM97006621 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1509G>T p.E503D 23:85270913-85270913 6
37 COSM96524396 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
38 COSM130605261 ZNF7 lung,NS,carcinoma,small cell carcinoma c.701G>C p.G234A 8:144842096-144842096 6
39 COSM89464457 ZNF7 lung,NS,carcinoma,small cell carcinoma c.281-3883G>C p.? 8:144842096-144842096 6
40 COSM129405109 ZNF7 lung,NS,carcinoma,small cell carcinoma c.248-3883G>C p.? 8:144842096-144842096 6
41 COSM110827987 ZNF7 lung,NS,carcinoma,small cell carcinoma c.1022G>C p.G341A 8:144842096-144842096 6
42 COSM130688921 ZNF7 lung,NS,carcinoma,small cell carcinoma c.989G>C p.G330A 8:144842096-144842096 6
43 COSM141336221 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
44 COSM122146768 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
45 COSM85394970 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
46 COSM92174992 ZNF660 lung,NS,carcinoma,small cell carcinoma c.575G>A p.C192Y 3:44594768-44594768 6
47 COSM86006104 ZNF653 lung,NS,carcinoma,small cell carcinoma c.808C>T p.P270S 19:11487655-11487655 6
48 COSM86006115 ZNF653 lung,NS,carcinoma,small cell carcinoma c.346C>T p.R116W 19:11496163-11496163 6
49 COSM105713312 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 6
50 COSM105035820 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 6

Expression for Lung Non-Squamous Non-Small Cell Carcinoma

Search GEO for disease gene expression data for Lung Non-Squamous Non-Small Cell Carcinoma.

Pathways for Lung Non-Squamous Non-Small Cell Carcinoma

Pathways related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 VEGFA RET PDCD1LG2 PDCD1 KRAS KIF5B
2
Show member pathways
13.87 VEGFA STK11 ROS1 KRAS KDR HRAS
3
Show member pathways
13.74 VEGFA ROS1 KRAS KDR HRAS FLT1
4
Show member pathways
13.59 ROS1 KRAS KDR HRAS FLT1 ERBB2
5
Show member pathways
13.58 VEGFA ROS1 KRAS KDR HRAS FLT1
6
Show member pathways
13.47 PDCD1LG2 PDCD1 KRAS KIF5B HRAS ERBB2
7
Show member pathways
13.46 ROS1 KRAS KDR HRAS FLT1 ERBB2
8
Show member pathways
13.36 ROS1 KRAS KDR HRAS FLT1 ERBB2
9
Show member pathways
13.29 VEGFA ROS1 KRAS KDR HRAS FLT1
10
Show member pathways
13.09 STK11 KRAS KDR HRAS FLT1 EGFR
11
Show member pathways
13 VEGFA STK11 KRAS KDR HRAS FLT1
12
Show member pathways
12.99 ROS1 KDR FLT1 ERBB2 EGFR ALK
13
Show member pathways
12.94 VEGFA KRAS KDR HRAS FLT1 ERBB2
14
Show member pathways
12.83 VEGFA RET KRAS HRAS ERBB2 EGFR
15 12.82 VEGFA RET KRAS HRAS ERBB2 EML4
16 12.79 VEGFA KRAS KDR HRAS FLT1 ERBB2
17
Show member pathways
12.77 VEGFA KRAS KDR HRAS FLT1 EGFR
18 12.59 VEGFA KRAS HRAS ERBB2 EGFR
19
Show member pathways
12.54 VEGFA KRAS KDR HRAS ERBB2 EGFR
20
Show member pathways
12.53 RET KRAS KIF5B HRAS ERBB2 EML4
21
Show member pathways
12.47 KRAS KDR HRAS FLT1 ERBB2 EGFR
22
Show member pathways
12.46 VEGFA KRAS KDR HRAS FLT1 EGFR
23
Show member pathways
12.45 STK11 KRAS KDR HRAS FLT1 ERBB2
24
Show member pathways
12.44 VEGFA KDR HRAS FLT1 EGFR
25
Show member pathways
12.42 VEGFA KRAS KDR HRAS
26 12.42 VEGFA RET KDR FLT1 ERBB2 EGFR
27
Show member pathways
12.4 PDCD1 KRAS HRAS EML4 EGFR CTLA4
28
Show member pathways
12.37 KRAS HRAS ERBB2 EGFR
29
Show member pathways
12.37 VEGFA KRAS KDR HRAS FLT1 EGFR
30
Show member pathways
12.35 KRAS HRAS ERBB2 EGFR
31
Show member pathways
12.34 VEGFA KRAS HRAS EGFR
32 12.31 VEGFA KRAS KDR HRAS ERBB2 EGFR
33
Show member pathways
12.3 ROS1 KRAS KDR HRAS FLT1 ERBB2
34
Show member pathways
12.27 KRAS KDR HRAS FLT1 ERBB2 EGFR
35
Show member pathways
12.26 PDCD1LG2 PDCD1 CTLA4 CD274
36 12.23 KRAS HRAS ERBB2 EGFR
37 12.2 VEGFA STK11 KRAS EGFR
38
Show member pathways
12.19 KRAS HRAS ERBB2 EGFR
39 12.18 PDCD1LG2 PDCD1 CTLA4 CD274
40
Show member pathways
12.14 STK11 KRAS HRAS EGFR
41
Show member pathways
12.11 KRAS HRAS ERBB2 EGFR
42 12.01 VEGFA FLT1 ERBB2 EGFR
43
Show member pathways
12 KRAS HRAS ERBB2 EGFR
44
Show member pathways
11.91 VEGFA KDR HRAS FLT1
45
Show member pathways
11.89 VEGFA ERBB2 EGFR
46 11.89 VEGFA FLT1 CTLA4
47
Show member pathways
11.88 KRAS HRAS EGFR
48 11.86 KRAS HRAS EGFR
49
Show member pathways
11.83 RET KRAS KDR HRAS FLT1
50
Show member pathways
11.75 VEGFA TYMS EGFR

GO Terms for Lung Non-Squamous Non-Small Cell Carcinoma

Cellular components related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 ROS1 RET PDCD1LG2 PDCD1 KRAS KDR
2 membrane GO:0016020 9.91 VEGFA TYMS STK11 ROS1 RET PDCD1LG2
3 perinuclear region of cytoplasm GO:0048471 9.8 ROS1 KIF5B HRAS ERBB2 EGFR CTLA4
4 integral component of plasma membrane GO:0005887 9.76 ROS1 RET KDR FLT1 ERBB2 EGFR
5 endosome GO:0005768 9.73 RET KDR FLT1 ERBB2 EGFR CD274
6 membrane raft GO:0045121 9.71 RET KRAS KDR EGFR
7 receptor complex GO:0043235 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Biological processes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 VEGFA ROS1 RET KRAS HRAS ERBB2
2 multicellular organism development GO:0007275 10.15 VEGFA ROS1 RET PDCD1 KDR FLT1
3 phosphorylation GO:0016310 10.08 STK11 ROS1 RET KDR FLT1 ERBB2
4 positive regulation of cell proliferation GO:0008284 10.07 VEGFA KRAS KDR HRAS FLT1 ERBB2
5 positive regulation of gene expression GO:0010628 10.06 VEGFA RET KRAS HRAS ERBB2
6 protein phosphorylation GO:0006468 10.06 STK11 ROS1 RET KDR FLT1 ERBB2
7 cell surface receptor signaling pathway GO:0007166 9.99 PDCD1LG2 HRAS ERBB2 EGFR CD274
8 MAPK cascade GO:0000165 9.97 RET KRAS HRAS ERBB2 EGFR
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 VEGFA KDR HRAS EGFR
10 positive regulation of protein kinase B signaling GO:0051897 9.93 VEGFA RET ERBB2 EGFR
11 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA KRAS KDR HRAS ERBB2 EGFR
12 positive regulation of cell migration GO:0030335 9.91 VEGFA RET KDR HRAS FLT1 EGFR
13 protein autophosphorylation GO:0046777 9.88 STK11 KDR FLT1 ERBB2 EGFR ALK
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 VEGFA KDR FLT1
15 liver development GO:0001889 9.84 KRAS HRAS EGFR
16 positive regulation of epithelial cell proliferation GO:0050679 9.84 VEGFA HRAS ERBB2 EGFR
17 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.81 VEGFA KDR FLT1
18 T cell costimulation GO:0031295 9.81 PDCD1LG2 PDCD1 CTLA4 CD274
19 positive regulation of MAPK cascade GO:0043410 9.8 VEGFA RET KDR HRAS FLT1 ERBB2
20 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ROS1 RET KDR FLT1 ERBB2 EGFR
21 negative regulation of T cell proliferation GO:0042130 9.77 PDCD1LG2 CTLA4 CD274
22 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.76 VEGFA KDR FLT1
23 peptidyl-tyrosine autophosphorylation GO:0038083 9.75 ROS1 KDR EGFR
24 regulation of ERK1 and ERK2 cascade GO:0070372 9.73 ROS1 ERBB2 EGFR
25 vascular endothelial growth factor signaling pathway GO:0038084 9.72 VEGFA KDR FLT1
26 positive regulation of phospholipase C activity GO:0010863 9.67 HRAS FLT1
27 positive regulation of positive chemotaxis GO:0050927 9.66 VEGFA KDR
28 tetrahydrofolate metabolic process GO:0046653 9.65 TYMS DHFR
29 vascular wound healing GO:0061042 9.65 VEGFA KDR
30 response to isolation stress GO:0035900 9.64 KRAS HRAS
31 negative regulation of ERBB signaling pathway GO:1901185 9.63 ERBB2 EGFR
32 positive regulation of MAP kinase activity GO:0043406 9.63 VEGFA KRAS HRAS FLT1 ERBB2 EGFR
33 tetrahydrofolate biosynthetic process GO:0046654 9.62 GART DHFR
34 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 VEGFA KDR
35 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.61 VEGFA KDR
36 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 ROS1 RET KDR FLT1 ERBB2 EGFR
37 positive regulation of kinase activity GO:0033674 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Molecular functions related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.1 TYMS STK11 ROS1 RET KDR GART
2 ATP binding GO:0005524 10.07 STK11 ROS1 RET KIF5B KDR GART
3 nucleotide binding GO:0000166 9.93 STK11 ROS1 RET KRAS KIF5B KDR
4 kinase activity GO:0016301 9.92 STK11 ROS1 RET KDR FLT1 ERBB2
5 protein kinase activity GO:0004672 9.86 STK11 ROS1 RET KDR FLT1 ERBB2
6 protein phosphatase binding GO:0019903 9.69 ROS1 ERBB2 EGFR
7 growth factor binding GO:0019838 9.61 KDR FLT1 ERBB2
8 protein tyrosine kinase activity GO:0004713 9.5 ROS1 RET KDR FLT1 ERBB2 EGFR
9 sequence-specific mRNA binding GO:1990825 9.49 TYMS DHFR
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.48 KDR FLT1
11 LRR domain binding GO:0030275 9.46 STK11 KRAS
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Sources for Lung Non-Squamous Non-Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....